Jens-Peter Marschner, a medical doctor and expert in drug development, has joined Zelluna Immunotherapy AS as chief medical officer to help advance the company’s lead T cell receptor product into the clinic. Dr Marschner joins from AbbVie Inc where he was the medical lead for oncology for Western Europe and Canada. Prior to this, he was CMO for Affimed NV in Germany where he was responsible for the development of that company’s bispecific antibodies. Based in Norway, Zelluna is developing non-engineered tumour specific T cell receptors for cancer that have been isolated from patients who survived cancer vaccine trials.
Zelluna Immunotherapy announced the appointment on 25 June 2019.
Copyright 2019 Evernow Publishing Ltd.